Digital pathology market was valued at $1,442.0 million in 2025 and is projected to reach $10,193.4 million by 2035, growing at a CAGR of 21.7% during the forecast period (2026-2035). Artificial Intelligence (AI) and Machine Learning (ML) are increasingly integrated into digital pathology workflows, representing a key trend in the global market. These technologies are being embedded within pathology software to automate image analysis, detect anomalies, and classify tissue samples with greater precision. AI/ML tools also support the quantification of biomarkers and tumor characteristics, enabling more accurate and reproducible assessments. By reducing inter-observer variability, these systems contribute to faster and more consistent diagnostic outcomes. In oncology, AI-driven applications are being utilized for early cancer detection and improved disease classification. The adoption of AI and ML reflects a broader shift toward data-driven, computational pathology, enhancing both clinical and research capabilities.

Global ultrasound market was valued at $7.4 billion in 2025 and is growing at a CAGR of 5.7% during the forecast period (2026-2035). Regulatory approvals for AI-enabled cardiac imaging solutions are strengthening trust in software-assisted ultrasound technologies among healthcare providers. This growing regulatory validation is encouraging hospitals and health systems to integrate AI-guided workflows into routine diagnostic and point-of-care ultrasound practices. As a result, ultrasound adoption is expanding beyond traditional imaging departments into decentralized care settings, supporting higher procedure volumes and broader end-user participation. These developments are contributing to the sustained growth of the global ultrasound market by improving device utilization, addressing workforce constraints, and enhancing diagnostic consistency. For instance, in January 2026, UltraSight received FDA clearance to expand its AI-guided Echo Stewardship Platform, enabling compatibility with various ultrasound systems, including handheld and cart-based devices. This expansion allows health systems to utilize their existing ultrasound equipment for focused cardiac ultrasound (FoCUS), facilitating real-time AI-assisted imaging that enhances quality and reduces variability in care. By training non-sonographer providers, such as Advanced Practice Providers (APPs), to perform diagnostic-quality FoCUS exams under physician oversight, the program aims to alleviate staffing challenges and streamline clinical workflows while maintaining professional review standards.

Global surface disinfectant market was valued at $4.5 billion in 2025 and is growing at a CAGR of 4.6% during the forecast period (2026-2035). Oxidizing agents play an essential role in surface disinfectants by effectively eliminating a broad spectrum of microorganisms, including bacteria, viruses, and fungi. These compounds, such as hydrogen peroxide, peracetic acid, and chlorine-based chemicals, work by disrupting the cellular components of pathogens through oxidation, leading to their inactivation. Their strong antimicrobial activity makes them suitable for high-risk environments like hospitals, laboratories, and pharmaceutical facilities. Oxidizing disinfectants are valued for their rapid action, minimal residue, and ability to reduce cross-contamination. They are often formulated in liquids, sprays, or wipes to provide versatile, reliable surface hygiene across diverse applications.

Global smartwatch market was valued at $40.7 billion in 2025 and is growing at a CAGR of 8.0% during the forecast period (2026-2035). Smartwatches play a significant role in medical and health monitoring by providing continuous, real-time tracking of key physiological parameters. They measure heart rate, blood oxygen levels, sleep patterns, and stress indicators, enabling users to gain insights into their overall well-being. Advanced models offer electrocardiogram (ECG) and irregular heartbeat detection, assisting in early identification of potential health issues. Integration with mobile health apps allows data storage, trend analysis, and sharing with healthcare providers. By combining convenience with proactive monitoring, smartwatches support preventive care, encourage healthier lifestyles, and empower individuals to make informed decisions about their health.

Sleep aid market was valued at $48.5 billion in 2025 and is growing at a CAGR of 6.1% during the forecast period (2026-2035). Growing recognition of sleep disorders, coupled with rising stress levels worldwide, is fueling the demand for more effective insomnia treatments, thereby driving the expansion of the sleep aid market. In line with this trend, pharmaceutical companies are increasingly focusing on developing novel therapies that target the underlying mechanisms of sleep regulation. For instance, in August 2025, Eisai launched its in-house developed anti-insomnia drug DAYVIGO (lemborexant) in China for treating adults with insomnia, impacting sleep onset and maintenance. DAYVIGO is a dual orexin receptor antagonist, acting by competitively binding to OX1R and OX2R receptors, regulating sleep-wake rhythm differently than conventional treatments like benzodiazepines. This drug may enhance sleep onset and maintenance by inhibiting wakefulness. Insomnia affects 15% of adults in China, with around 172.5 million individuals affected, highlighting the increasing need for novel treatment solutions beyond current options.

Global protein engineering market was valued at $3.5 billion in 2025 and is growing at a CAGR of 16.4% during the forecast period (2026-2035). Increasing investments in R&D for monoclonal antibodies, engineered proteins, and next-generation biologics are driving market growth and fueling demand for efficient protein engineering solutions. Additionally, this trend is reflected in recent funding activities that support the development of integrated, in-house protein engineering and validation capabilities aimed at accelerating antibody and biologics discovery. For instance, in January 2026, Nuclera successfully extended its Series C funding to a total of $87 million, including an additional $12 million financing extension aimed at enhancing its eProtein Discovery capabilities for antibody engineering. The funding, led by Elevage Medical Technologies and Jonathan Milner, alongside existing investors, will focus on integrating antibody expression and binding validation into Nuclera's benchtop eProtein Discovery System. This initiative will facilitate rapid, in-house multiplex protein screening and characterization, essential for advancing AI-enabled protein engineering and meeting the industry's demands for high-quality datasets in biologics discovery.

Global Probiotics market was valued at $76.2 billion in 2025 and is growing at a CAGR of 8.2% during the forecast period (2026-2035). Probiotics are live microorganisms that, when consumed in adequate amounts, support the balance of beneficial bacteria in the human body, particularly in the digestive system. They are commonly incorporated into foods, beverages, and dietary supplements due to their association with digestive health and overall well-being. Probiotics function by helping maintain microbial balance, supporting normal gut function, and contributing to the body’s natural defense mechanisms. Their use has expanded beyond traditional dairy products into a wider range of food and beverage formats, reflecting changing consumer preferences and advancements in formulation and storage technologies. Probiotic-enriched dairy products dominate the market due to high consumer demand for gut health, digestive benefits, and overall wellness.

Global power bank market was valued at $14.0 billion in 2025 and is growing at a CAGR of 6.1% during the forecast period (2026-2035). Growing deployment of utility-scale renewable technologies, including solar, battery energy storage, and hybrid projects, is revealing a heightened necessity for interconnection deposits, which in turn necessitates structured financing solutions to effectively progress projects through development pipelines, thereby driving market growth. This trend is increasingly reflected in recent financing arrangements within the renewable energy development ecosystem, where dedicated capital is being used to address upfront interconnection requirements and accelerate project advancement. For instance, in December 2025, $8 million loan secured by PowerBank will fund interconnection deposits for a portfolio of 34 MW of solar power, battery energy storage, and hybrid projects. These deposits, required by utilities for interconnection and refundable if projects don't reach commercial operation, enable PowerBank to leverage low-cost capital to grow its Independent Power Producer portfolio. The loan allows for a revolving source of capital as projects are monetized or operational, with potential for an increase up to $12 million. It is secured against project assets, and no shares are issuable in connection with the loan.

Global non-invasive cancer diagnosis market was valued at $38.6 billion in 2025 and is growing at a CAGR of 12.2% during the forecast period (2026-2035). Molecular diagnostics play a critical role in the global non-invasive cancer diagnosis market by enabling highly sensitive detection of circulating tumor DNA (ctDNA) and other biomarkers in blood. These tests support early identification of cancer recurrence and residual disease, often months before conventional imaging methods can detect abnormalities. By providing precise, real-time insights, molecular diagnostics allow clinicians to personalize monitoring strategies, optimize treatment decisions, and improve patient outcomes. The minimally invasive nature of these tests enhances patient compliance and reduces reliance on traditional biopsies, driving adoption across healthcare systems and contributing significantly to the growth and innovation of the non-invasive cancer diagnosis market.

The global lung cancer therapeutics market was valued at $37,500 million in 2024 and is growing at a CAGR of 10.3% during the forecast period (2026-2035). Regulatory validation of next-generation immunotherapies is increasing physician confidence and shifting the market from traditional chemotherapy to immune-based treatments, thereby accelerating the adoption of advanced immunotherapy for advanced small-cell lung cancer. This trend is evidenced by recent regulatory actions supporting novel immunotherapies. For instance, in November 2025, FDA granted full approval to the immunotherapy drug tarlatamab (Imdelltra) for adults with advanced small-cell lung cancer (SCLC) that has spread after platinum-based chemotherapy. Tarlatamab functions as a bispecific T cell engager, linking tumor cells to T cells to enhance the immune response against cancer. In a study of 509 patients, those treated with tarlatamab exhibited a 40% reduction in death risk compared to standard chemotherapy, even among patients with extensive disease spread, where the five-year survival rate is typically below 10%.